Objective To evaluate the quality of life and treatment of patients with primary biliary cholangitis( PBC) using the PBC-40 scale. Methods The PBC-40 scale was used to perform an investigation of 37 patients who were diagnosed with PBC and received continuous treatment in Department of Gastroenterology,The First Affiliated Hospital of Air Force Medical University,from January 2017 to December 2018. With reference to patients' baseline biochemical parameters and pathological staging,the scores of the six domains of the PBC-40 scale,i. e.,“symptom”,“pruritus”,“weakness”,“cognitive function”,“social function”,and “emotional function”,were analyzed. The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups,and an analysis of variance was used for comparison between multiple groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups,and the Kruskal-Wallis H test was used for comparison between multiple groups. The paired-samples Wilcoxon signed rank sum test was used for comparison of pruritus score before and after treatment,and the paired samples t-test was used for comparison of weakness score before and after treatment. A Spearman analysis was used to investigate correlation.Results In the PBC-40 scale,the scores of symptom,pruritus,weakness,cognitive function,social function,and emotional function were 16. 5 ± 4. 3,5. 2 ± 3. 3,26. 4 ± 8. 3,15. 3 ± 5. 1,25. 4 ± 8. 4,and 8. 1 ± 2. 7,respectively. A stratified analysis was performed for the patients aged < 50 years,50-60 years,and > 60 years,and the results showed that there was a significant difference in the score of pruritus between the different age groups( χ2= 8. 290,P = 0. 016). The PBC patients with a body mass index of ≥24 kg/m2 had significantly lower scores of symptom and cognitive function than those with a body mass index of < 24 kg/m2( symptom: Z =-2. 222,P =0. 025; cognitive function: t = 2. 255,P = 0. 030). The patients with positive anticentromere antibody had a significantly higher score of weakness than those with negative anticentromere antibody( t = 3. 453,P = 0. 001). The score of pruritus was positively correlated with alkaline phosphatase( ALP)( R2= 0. 325,P = 0. 049) and gamma-glutamyl transpeptidase( GGT)( R2= 0. 402,P = 0. 014). Conclusion The PBC-40 scale can be used to evaluate the quality of life of Chinese patients with PBC. High levels of ALP and GGT may predict low quality of life.
[1] WANG L,CHANG YH,HAN Y. Pathogenesis and advances in treatment of primary biliary cholangitis[J]. Int J Dig Dis,2019,39(2):81-85.(in Chinese)王璐,常英昊,韩英.原发性胆汁性胆管炎的发病机制及治疗进展[J].国际消化病杂志,2019,39(2):81-85.
|
[2] BEUERS U,KREMER AE,BOLIER R,et al. Pruritus in cholestasis:Facts and fiction[J]. Hepatology,2014,60(1):399-407.
|
[3] JOPSON L,JONES DE. Fatigue in primary biliary cirrhosis:Prevalence,pathogenesis and management[J]. Dig Dis,2015,33(Suppl 2):109-114.
|
[4] SUN Y,ZHANG W,EVANS JF,et al. Autotaxin,pruritus and primary biliary cholangitis(PBC)[J]. Autoimmun Rev,2016,15(8):795-800.
|
[5] JACOBY A,RANNARD A,BUCK D,et al. Development,validation,and evaluation of the PBC-40,a disease specific health related quality of life measure for primary biliary cirrhosis[J]. Gut,2005,54(11):1622-1629.
|
[6] NEWTON JL,BHALA N,BURT J,et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure[J]. J Hepatol,2006,44(4):776-783.
|
[7] YAGI M,TANAKA A,ABE M,et al. Symptoms and healthrelated quality of life in Japanese patients with primary biliary cholangitis[J]. Sci Rep,2018,8(1):12542.
|
[8] ZHANG S,WANG L,ZHAO LL,et al. Analysis of the relationship between health-related quality of life(primary biliary cholangitis-40)and clinical presentations of patients with primary biliary cholangitis[J]. Clin J Rheumatol,2018,22(12):798-801.(in Chinese)张硕,王立,赵丽伶,等.原发性胆汁性胆管炎生活质量指标PBC-40与临床指标相关性分析[J].中华风湿病学杂志,2018,22(12):798-801.
|
[9] LINDOR KD,BOWLUS CL,BOYER J,et al. Primary biliary cholangitis:2018 practice guidance from the american association for the study of liver diseases[J]. Hepatology,2019,69(1):394-419.
|
[10] HIRSCHFIELD GM,DYSON JK,ALEXANDER G,et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut,2018,67(9):1568-1594.
|
[11] CARBONE M,MELLS GF,PELLS G,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology,2013,144(3):560-569.
|
[12] LU H,ZHANG W. Clinical significance of anticentromere antibody in various autoimmune diseases[J]. Chin J Allergy Clin Immunol,2018,12(6):650-654.(in Chinese)卢慧,张文.抗着丝点抗体在多种疾病的临床意义[J].中华临床免疫和变态反应杂志,2018,12(6):650-654.
|
[13] WANG MC,XU AF,TANG XF. Serological and imaging study of positive anti-centromere antibody in patients with primary biliary cirrhosis[J]. Chin J Health Lab Tec,2018,28(7):827-829.(in Chinese)王妙婵,徐爱芳,汤晓飞.抗着丝点抗体阳性原发性胆汁性肝硬化患者血清学及影像学特征分析[J].中国卫生检验杂志,2018,28(7):827-829.
|
[14] NAKAMURA M,KOMORI A,ITO M,et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis[J]. Hepatol Res,2007,37(Suppl 3):s412-s419.
|
[15] HEGADE VS,MELLS GF,FISHER H,et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the united kingdom[J]. Clin Gastroenterol Hepatol,2019,17(7):1379-1387. e3.
|
[16] REIG A,SESP,PARS A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J]. Am J Gastroenterol,2018,113(1):49-55.
|
[17] HEGADE VS,KENDRICK SF,DOBBINS RL,et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:A double-blind,randomised,placebo-controlled,crossover,phase 2a study[J]. Lancet,2017,389(10074):1114-1123.
|